Related Experiment Video
Updated: Jun 11, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Ramucirumab (IMC-1121B): a novel attack on angiogenesis
Jennifer L Spratlin1, Karen E Mulder, John R Mackey
1Department of Medical Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada. jennifer.spratlin@albertahealthservices.ca
Future Oncology (London, England)
|July 14, 2010
Summary
Ramucirumab, a novel monoclonal antibody, specifically targets VEGF receptor-2 to inhibit cancer angiogenesis. Early trials show promising safety and efficacy in solid tumors, offering a new antiangiogenic therapy option.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Angiogenesis is crucial for solid tumor growth and metastasis.
- Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) drives tumor angiogenesis.
- Current antiangiogenic therapies have limitations.
Purpose of the Study:
- To review current data on ramucirumab, a VEGFR-2 inhibitor.
- To compare ramucirumab with existing antiangiogenic agents.
- To highlight ramucirumab's potential in solid tumor treatment.
Main Methods:
- Review of Phase I clinical trial data for ramucirumab.
- Pharmacological analysis of ramucirumab's specific VEGFR-2 inhibition.
- Comparative analysis with approved angiogenesis inhibitors.
Main Results:
- Ramucirumab demonstrated safety across various doses in Phase I trials.
- Early evidence of stable disease and partial responses observed.
- Ramucirumab specifically and potently inhibits VEGFR-2.
Conclusions:
- Ramucirumab represents a targeted approach to inhibiting angiogenesis.
- The drug shows potential as an effective antiangiogenic therapy for solid tumors.
- Further clinical evaluation is warranted to confirm its therapeutic value.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.